Wrong recommendation from CPIC for capecitabine and fluorouracil

[krukanna]

• Do you want to request a feature or report a bug? bug

• What is the current behavior? Exactly the same recommendation for capecitabine and fluorouracil for phenotype Intermediate Metabolizer

Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).

• What is the expected behavior?

Recommendation in CPIC publication for Intermediate Metabolizer are different for different activity score. Correct recommendation should be:

Reduce starting dose by 25% to 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).

• Please tell us about your environment:
  • PharmCAT Version: 2.2.1

[whaleyr]

Thanks for finding this, we've found the source of the issue and it will be fixed in the next release.

[whaleyr]

This has been fixed in v2.2.2. Download the new JAR and you should be good to go.

[mwcarrillo]

This was actually not an error. The CPIC guideline was updated in November 2018, after the manuscript was released - a reason to consult the CPIC or PharmGKB websites (cpicpgx.org or pharmgkb.org) where updates are posted. See https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/ for the full explanation of why the PharmCAT data was correct. Therefore, this was rolled back to the updated guidance.